Identified an 'alarm clock' of a leukemia-causing oncogene

October 08, 2015

of IDIBELL, ICREA researcher and Professor of Genetics at the University of Barcelona, shows how a mutation in a gene results the activation of a gene that triggers leukemia.

"Recently it has been discovered the existence of mutations in the DNMT3A gene in leukemia. It seemed that history stopped here. But this gene is responsible for silencing other genes that should not be active in the cell; so we wonder which DNA sequence was being "awakened" by this mutation in leukemias "explained Manel Esteller, director of the study.

"By analyzing the entire genome of leukemia cells carrying the mutation, we realized that the activated target gene was called oncogene MEIS1. This is a powerful gene inducing acute myeloid leukemia which its proleucémica function was known, but not as it gets underway. The mutation of another gene explains it"says the researcher.

"We can imagine it as a house of cards. If you remove the card from the bottom row (DNMT3A) just falling all upper layers, such as oncogene MEIS1. The finding, in addition to its usefulness in predicting patients with poor prognosis leukemias, suggests that this subtype of leukemia may be sensitive to drugs that have as target the two genes studied".
-end-
Article:

HJ Ferreira, Heyn H, Vizoso M, C Moutinho, Vidal E, Gomez A, Martinez-Cardus A, Simo-Riudalbas L, S Moran, Jost E, Esteller M. DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor in acute MEIS1 myeloid leukemia. Oncogene, October 5th, 2015.

IDIBELL-Bellvitge Biomedical Research Institute

Related Leukemia Articles from Brightsurf:

New therapeutic approach against leukemia
Using an RNA molecule complex, researchers can prevent retention of cancer stem cell in their tumor supporting niche

Nanoparticle for overcoming leukemia treatment resistance
One of the largest problems with cancer treatment is the development of resistance to anticancer therapies.

Key gene in leukemia discovered
Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.

Vitamin B6, leukemia's deadly addiction
Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6.

Artificial intelligence tracks down leukemia
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability.

Milestone reached in new leukemia drug
Using a chemical compound called YKL-05-099, a team of cancer researchers from CSHL and the Dana Farber Institute was able to target the Salt-Inducible Kinase 3 (SIK3) pathway and extend survival in mice with MLL leukemia.

The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.

Towards a safer treatment for leukemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the Children's Cancer Institute, Australia, have found a safer treatment for a specific type of leukemia.

Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.

An atlas of an aggressive leukemia
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.

Read More: Leukemia News and Leukemia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.